Join to View Full Profile
Institutes Of HealthBldg 10Bethesda, MD 20892
Phone+1 301-496-1597
Fax+1 301-496-2363
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joel Moss, MD is a pulmonologist in Bethesda, Maryland. He is currently licensed to practice medicine in Maryland and New York.
Education & Training
Johns Hopkins UniversityResidency, Internal Medicine, 1972 - 1974
New York University School of MedicineClass of 1972
Certifications & Licensure
NY State Medical License 1974 - 2026
MD State Medical License 1974 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- Evolution of Diffusing Capacity of the Lungs for Carbon Monoxide in Lymphangioleiomyomatosis: Historical Perspectives and the Role of Advanced Imaging.Bennett E Yang, Jason M Elinoff, Adrienne E Campbell-Washburn, Han Wen, Joel Moss
Chest. 2024-11-21 - 1 citationsUnsupervised Exercise in Interstitial Lung Disease: A Delphi Study to Develop a Consensus Preparticipation Screening Tool for Lymphangioleiomyomatosis.Claire E Child, Lawrence A Ho, Daniel Lachant, Nishant Gupta, Joel Moss
Chest. 2024-11-01 - Extracellular Vesicle Inhibitors Enhance Cholix-Induced Cell Death via Regulation of the JNK-Dependent Pathway.Kazuya Ozaki, Hiyo Nagahara, Asaka Kawamura, Takashi Ohgita, Sachika Higashi
Toxins. 2024-08-29
Press Mentions
Public Advisory Roundtable Amplifies Patient Voices Through Forum, Symposium, SpeakersApril 26th, 2022- Worldwide LAM Awareness MonthJune 18th, 2021
- Subtilase Cytotoxin Induces a Novel Form of Lipocalin 2, Which Promotes Shiga-Toxigenic Escherichia Coli SurvivalNovember 3rd, 2020
- Join now to see all
Grant Support
- ADP-ribosylation CyclesNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Clinical and Translational ResearchNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- ADP-ribosylation CyclesNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)NATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)NATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Clinical and Translational ResearchNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
